KBI Biopharma Acquires Alliance Protein Laboratories, Expands Biophysical Characterization Capabilities
15.6.2017 17:14 | Business Wire
KBI Biopharma, Inc. (KBI) has agreed to acquire the assets of San Diego-based Alliance Protein Laboratories (Alliance), a leading analytical services company specializing in biophysical characterization of biopharmaceuticals. Founded in 1998, Alliance is well known and highly regarded around the world for its expertise in characterization of therapeutic proteins, peptides, nucleic acids and vaccines.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170615005738/en/
Recognized as the foremost expert in analytical ultracentrifugation (AUC), an essential technology for determining physical stability, association state, molecular weight and quantitative characterization of protein aggregates, Alliance was also a pioneer in the use of biophysical methods to demonstrate that the higher order structure of biosimilar proteins and generic peptide therapeutics is comparable to the innovator product. Alliance has supported biosimilar developers since 2003, and has experience across an exceptionally broad range of biosimilar targets.
This acquisition will complement KBI’s extensive analytical and biophysical characterization capabilities, and expands those capabilities to include AUC. All of Alliance’s staff, including co-founders Tsutomu Arakawa, Ph.D. and John Philo, Ph.D. will join KBI through the acquisition with Tsutomu and John continuing to oversee operations in the San Diego-based laboratory.
This announcement marks another major expansion announced by KBI in 2017, starting with the addition of its cell therapy development and manufacturing operations in The Woodlands, TX this past February. In May, the company announced plans to expand its capabilities at both its Durham, NC and Boulder, CO facilities. On June 14, it was announced that parent company JSR Life Sciences would acquire Geneva-based Selexis SA to integrate with KBI to provide full gene to GMP solutions for clients.
“We are extremely excited to welcome Alliance Protein Labs, Dr. Philo and Dr. Arakawa to KBI Biopharma,” said KBI President Tim Kelly, Ph.D. “Alliance is a pioneer in the application of biophysical characterization to accelerate biopharmaceutical development, and their expertise in AUC, circular dichroism, light scattering and other techniques has earned the respect and admiration of our entire industry. The leadership of Tsutomu and John in San Diego adds an exciting new dimension for KBI to better serve our clients.”
“Alliance has found the ideal partner in KBI Biopharma,” said Alliance President Tsutomu Arakawa, Ph.D. “We can now offer our clients a much broader range of analytical characterization services in combination with KBI. KBI’s mission to accelerate biopharmaceutical development aligns perfectly with the core values that drive Alliance. John and I are thrilled to build on the success of Alliance by partnering with KBI.”
To date, KBI has helped to advance more than 300 molecules in 68 unique health indications. With the addition of these expanded analytical capabilities, and by adding a laboratory facility on the West Coast, KBI will continue to accelerate an even broader range of drug development programs for its global client base.
About KBI Biopharma
KBI Biopharma is a biopharmaceutical Contract Development & Manufacturing Organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage biotech to academic/non-profit organizations to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.
KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical protein characterization techniques towards the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapies for our clients.
KBI was founded in 1996 and operates 4 facilities: Durham and Research Triangle Park (NC), Boulder (CO), and The Woodlands (TX).
About Alliance Protein Laboratories
Alliance Protein Laboratories is a contract research and consulting firm specializing in biophysical analysis. It offers a broad range of biophysical characterization services, contract purification services (research scale), and consulting services.
Alliance was founded in 1998 by Drs. Tsutomu Arakawa and John Philo, and was the first CRO with a focus on biophysical analysis of proteins and peptides. Its laboratory is located in the heart of the biotechnology cluster in San Diego, CA. Clients include over 400 companies, universities and non-profit institutes in North America, Europe, Asia, and Australia.
JSR Life Sciences & KBI Biopharma, Inc.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 23:15 | Tiedote
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 23:11 | Tiedote
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25 | Tiedote
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00 | Tiedote
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03 | Tiedote
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00 | Tiedote
Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme